Information Provided By: 
Fly News Breaks for July 24, 2019
EW
Jul 24, 2019 | 07:26 EDT
Canaccord analyst Jason Mills raised his price target on Edwards Lifesciences to $250 from $215 following Q2 results. The analyst believes the accelerating TAVR growth through the second half of the year in addition to TMTT growth will push the stock toward his price target. He believes large-cap investors should add to positions even after the stock's rise following its results. Mill reiterated his Buy rating on Edwards Lifesciences shares.
News For EW From the Last 2 Days
